Mereo Biopharma Group Plc ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $500KTTM through 30 Jun 2026
Net Income -$41.9MTTM through 30 Jun 2026
Free Cash Flow -$25.3MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 73.4% |
| Operating Margin | -8,021.4% |
| Net Margin | -8,375.6% |
Returns
-102.4%ROE
-91.2%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio10.46x
Net Debt-$41Mnet cash position
Cash & Equivalents$30.1M
Quality Metrics
Altman Z-Score-18.59
Piotroski F-Score2 / 9
FCF Margin-5,069.2%
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2025: $500K
Diluted EPS-$0.04TTMFY2025: $-0.05
Dividend
No dividend
Capital Allocation
R&D Spend$15M
Capex Intensity0.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Rare Disease Therapeutics | $500K | View detailsFocusing on regulatory engagement for setrusumab in pediatric patients and advancing partnering discussions for alvelestat. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.